Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2015 | Immuno-oncology opportunities for the treatment of lymphoma

Anton Hagenbeek • 4 Dec 2015
ASH 2015
Hodgkin Lymphoma Non-Hodgkin Lymphoma Antibodies Brentuximab vedotin Checkpoint inhibitors

At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Anton Hagenbeek, MD, PhD, from the University of Amsterdam, Amsterdam, Netherlands, discusses immuno-oncology mechanisms and pathways that can be targeted by immunotherapies for patients with Hodgkin lymphoma or non-Hodgkin lymphoma. Highlighted approaches that are being explored include immune checkpoint inhibitors and brentuximab vedotin, an anti-CD30 antibody-drug conjugate.

More from Anton Hagenbeek

23:19
12th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2014: Day 2 meeting highlights
Anton Hagenbeek et al. • 9 Apr 2015
16:39
iwNHL 2015 roundtable: The changing treatment landscape for non-Hodgkin lymphoma
Andrew Zelenetz et al. • 3 Oct 2015
2:18
Brentuximib vedotin therapy for Hodgkin lymphoma
Anton Hagenbeek • 9 Dec 2014
1:58
What should the future of cancer treatment and research look like?
Anton Hagenbeek • 9 Jun 2016

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals